{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:12:33Z","timestamp":1791357153449,"version":"4.3.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/wnf.0b013e3182aa38c4","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T14:07:59Z","timestamp":1383746879000},"page":"223-238","source":"Crossref","is-referenced-by-count":20,"title":["Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole"],"prefix":"10.1097","volume":"36","author":[{"given":"Sheng-Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin A.","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash S.","family":"Masand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Un","family":"Pae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R13-7-20210203","first-page":"14","article-title":"Asenapine: a clinical overview.","volume":"72","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-012-0026-x","article-title":"Lurasidone: in the treatment of schizophrenia.","volume":"27","year":"2013","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"R20-7-20210203","first-page":"S3","article-title":"Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed.","volume":"6","year":"2002","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"Suppl 6","key":"R21-7-20210203","first-page":"5","article-title":"Schizophrenia, antipsychotic drugs, and cardiovascular disease.","volume":"66","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 10","key":"R30-7-20210203","first-page":"5","article-title":"Receptor pharmacology of neuroleptics: relation to clinical effects.","volume":"60","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"R35-7-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","article-title":"Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.","volume":"65","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"7","key":"R37-7-20210203","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.","volume":"11","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"R61-7-20210203","first-page":"297","article-title":"Clinical evaluation of blonanserin for schizophrenia: a randomized study comparing blonanserin with risperidone (in Japanese).","volume":"11","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R63-7-20210203","first-page":"2059","article-title":"Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol.","volume":"10","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R64-7-20210203","first-page":"2241","article-title":"Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group) English abstract.","volume":"10","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R65-7-20210203","first-page":"135","article-title":"Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japanese) English abstract.","volume":"11","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"1","key":"R88-7-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1586\/ecp.12.70","article-title":"Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.","volume":"6","year":"2013","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e3182aa38c4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:15:39Z","timestamp":1620976539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201311000-00007"}},"subtitle":["Distinctive Clinical Characteristics of 5 Novel Atypical Antipsychotics"],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3182aa38c4","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}